County health officials say monkeypox cases have been declining since a late July spike, consistent with the national trend reported in a news briefing by the Centers for Disease Control and Prevention last Thursday.
“We were expecting to see a continuous doubling,” said Mpande Mwape, director of health services for the Pittsburgh community health center Allies for Health + Wellbeing, which supports those living with HIV. “I’m very, very happy to see a downward trend in cases,” she said.
As of Sept. 20, the county has recorded 66 cases.
Allegheny County Health Department’s medical epidemiologist Dr. Kristen Mertz said that “from the start, we were in better shape to combat the spread” of monkeypox compared to a virus like coronavirus.
This is partly due to differences in transmission: While coronavirus is airborne, monkeypox is largely transmitted through direct contact, so Dr. Mertz said they did not expect it to reach pandemic-level spread. And while the COVID-19 vaccines had to be developed, a vaccine for monkeypox already exists, made by the company Jynneos. These factors, combined with the mobilization of multiple prongs in virus response like education, widespread testing and vaccination, meant that clinics haven’t been too overwhelmed with monkeypox cases. The health department is still encouraging providers to test liberally.

Another important consideration for effective monkeypox response is equitable distribution of resources. So far, 540,000 doses of the Jynneos vaccine have been administered nationally for those jurisdictions reporting data, but the CDC recently found that white men have received more vaccine doses than people of other races — they make up almost half of people who have received their first dose, despite representing a quarter of cases.
Read More
Non-Hispanic Black men and Hispanic men, on the other hand, are testing positive for monkeypox at a higher rate than white men. Black men made up 12% of vaccinations but 38% of cases, while Hispanic men made up 21% of vaccinations but 25% of cases. Dr. Rochelle Walensky, the CDC’s director, reiterated the importance of distributing resources equitably among populations. “We continue to prioritize health equity in all the work we do,” she said in the briefing.
Allegheny County is experiencing the same trend. Ms. Mwape said about 70% of the people Allies has vaccinated have been white and 14% to 15% have been Black. Dr. Mertz said the majority of monkeypox cases reported to the health department have been in white people, but Black and Hispanic people are slightly overrepresented in the case counts. In terms of vaccination data, they are working to gather this data to understand more about the demographics of those getting vaccinated though the health department’s Immunization Clinic.
Because of the COVID-19 pandemic, health care providers at the health department and beyond are aware of disparities in access to health care and the impact this can have on marginalized groups. “We’ve been mindful of this since the beginning,” said Dr. Barbara Nightingale, deputy director for clinical services at Allegheny County Health Department. “We’re constantly working on onboarding new clinics and federally qualified health centers if people don’t have a primary care provider or insurance,” she said.
Allies is testing and vaccinating anyone for monkeypox regardless of patient status, but it requires appointments for testing. Allies is also working on setting up a monkeypox vaccine clinic aimed at helping people who historically have faced barriers in accessing treatment. “We are here to support the community effort,” she said.
Dr. Mertz said the health department’s goal is to eliminate monkeypox, but it’s too soon to tell if that will be possible. Dr. Nightingale said “we’ve made an excellent effort to contain this.”
The CDC also announced in the briefing that it is expanding research efforts on the experimental treatment tecovirimat, or TPoxx, as well as studying different routes of administering the Jynneos vaccine. New clinical trials opened on Sept. 8, including one actively recruiting at least 210 participants to measure the difference between administering the Jynneos vaccine in the traditional subcutaneous way – under the skin – versus giving it in a new intradermal way, between skin layers, which is meant to stretch the vaccine supply by using smaller amounts.
The trial is also testing whether one-tenth of a standard dose will be sufficient to prevent monkeypox infection. The CDC had received emergency use authorization to administer one-fifth of the standard dose intradermally on Aug. 9. Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), said this adjustment would “immediately double the amount of doses available on an international scale.”
Another trial, known as STOMP, or “the study of tecovirimat for human monkeypox virus,” is aiming to enroll 530 people who have tested positive for monkeypox and are eligible to receive TPoxx. People with severe skin conditions, those who are immunocompromised, and people who are breastfeeding are also eligible to participate. Open enrollment began on Sept. 8 and participants are still being accepted. Dr. Fauci also said that NIAID is studying TPoxx resistance. When response involves using only one drug to treat a contagious virus, chances increase that the body could become resistant to it.
Part of the White House monkeypox response has been to provide on-the-ground education and opportunities for vaccination at large events like Pride festivals. The Jynneos vaccine has been administered to more than 10,000 people at various Pride festivals across the country. At one festival in Atlanta, almost 70% of those who received one dose of the Jynneos vaccine identified as nonwhite, and nearly 50% as Black.
“Equity must remain the cornerstone of our response,” said Dr. Demetre Daskalakis, the White House monkeypox response deputy coordinator.
Dr. Daskalakis said monkeypox cases were down by nearly half since a peak in August. To maintain control over the spread, health officials want to employ a hyper-local strategy and start offering smaller events promoting education and vaccination in addition to the large events like Pride festivals.
Health experts in the briefing reported that monkeypox has been coinciding with other infections.
“Monkeypox is not an infection that exists in isolation,” said Dr. Daskalakis. Of those diagnosed with monkeypox, 61% also had either HIV or a sexually transmitted infection. This is likely due to the nature of how monkeypox spreads: through direct physical contact with the sores or with shared linens of an infected person, though monkeypox is not an STI and can be transmitted in other ways aside from sex. Dr. Daskalakis said these new statistics about co-occurrence point to where resources should be directed.
“The same people we need to test for HIV and sexually transmitted infections,” he said, “are the same people who need monkeypox-related services like testing, education, and vaccines.”
He encouraged health care providers to use their HIV and STI-related resources for monkeypox screening and testing.
Ms. Mwape, of Allies, said that although the clinic has noticed people who have previously tested positive for STIs come in with concern for monkeypox, there has not been much co-occurrence of monkeypox with STIs. But it has provided an opportunity to talk to patients about how to prevent STIs.
The CDC officials also discussed the importance of a mobilized community response — it’s not only government or healthcare, but community action and communication in general that will help corral this virus. “This is a toolkit, and you have to use every tool in a toolkit,” Dr. Daskalakis said.
Hanna Webster: hwebster@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.